Clinical characteristics and current treatment of age-related macular degeneration
- PMID: 25280900
- PMCID: PMC4292078
- DOI: 10.1101/cshperspect.a017178
Clinical characteristics and current treatment of age-related macular degeneration
Abstract
Age-related macular degeneration (AMD) is a multifactorial degeneration of photoreceptors and retinal pigment epithelium. The societal impact is significant, with more than 2 million individuals in the United States alone affected by advanced stages of AMD. Recent progress in our understanding of this complex disease and parallel developments in therapeutics and imaging have translated into new management paradigms in recent years. However, there are many unanswered questions, and diagnostic and prognostic precision and treatment outcomes can still be improved. In this article, we discuss the clinical features of AMD, provide correlations with modern imaging and histopathology, and present an overview of treatment strategies.
Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved.
Figures








Similar articles
-
New treatments for age-related macular degeneration.Age Ageing. 2007 Jan;36(1):8-10. doi: 10.1093/ageing/afl135. Age Ageing. 2007. PMID: 17264135 No abstract available.
-
Therapeutic modalities of exudative age-related macular degeneration.Med Arh. 2014;68(3):204-8. Med Arh. 2014. PMID: 25195354 Review.
-
Opportunities and Challenges in Translational Research: The Development of Photodynamic Therapy and Anti-Vascular Endothelial Growth Factor Drugs.J Law Med Ethics. 2021;49(1):19-24. doi: 10.1017/jme.2021.4. J Law Med Ethics. 2021. PMID: 33966647
-
Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.Br J Ophthalmol. 2011 Dec;95(12):1631-7. doi: 10.1136/bjo.2010.186361. Epub 2011 May 5. Br J Ophthalmol. 2011. PMID: 21546514 Review.
-
The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters.Graefes Arch Clin Exp Ophthalmol. 2014 Dec;252(12):1911-20. doi: 10.1007/s00417-014-2641-3. Epub 2014 Apr 29. Graefes Arch Clin Exp Ophthalmol. 2014. PMID: 24777708
Cited by
-
Bridging the gap of vision restoration.Front Cell Neurosci. 2024 Nov 21;18:1502473. doi: 10.3389/fncel.2024.1502473. eCollection 2024. Front Cell Neurosci. 2024. PMID: 39640234 Free PMC article. Review.
-
Pharmacological and Metabolic Significance of Bile Acids in Retinal Diseases.Biomolecules. 2021 Feb 16;11(2):292. doi: 10.3390/biom11020292. Biomolecules. 2021. PMID: 33669313 Free PMC article. Review.
-
Relationship Between Facial Melasma and Ocular Photoaging Diseases.Med Sci (Basel). 2025 May 16;13(2):61. doi: 10.3390/medsci13020061. Med Sci (Basel). 2025. PMID: 40407556 Free PMC article.
-
Off-Label Use of Bevacizumab in Patients Diagnosed with Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.Pharmaceuticals (Basel). 2024 Jul 29;17(8):1000. doi: 10.3390/ph17081000. Pharmaceuticals (Basel). 2024. PMID: 39204105 Free PMC article. Review.
-
Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration.J Ocul Pharmacol Ther. 2018 Dec;34(10):700-709. doi: 10.1089/jop.2018.0062. Epub 2018 Nov 9. J Ocul Pharmacol Ther. 2018. PMID: 30412448 Free PMC article. Clinical Trial.
References
-
- AREDS2 Study Group. 2013. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 309: 2005–2015. - PubMed
-
- Arnold JJ, Sarks SH, Killingsworth MC, Sarks JP 1995. Reticular pseudodrusen. A risk factor in age-related maculopathy. Retina 15: 183–191. - PubMed
-
- Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Mones JM, Potter MJ, et al. 2002. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: Three-year results of an open-label extension of 2 randomized clinical trials—TAP Report no. 5. Arch Ophthalmol 120: 1307–1314. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical